Clinical trial · Observational
Understanding the Burden of ACC Through the Eyes of Patients
NCT04706845CI-TRIAL-00070093completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is a comprehensive, cross-sectional study conducted with approximately 40-60 individuals affected by ACC who may know the results of molecular profiling of their tumor. Primary Objectives: * To identify the specific burdens faced by patients with ACC * To compare/contrast the burdens faced by patients with ACC at different disease stages (no evident disease, metastatic disease/watchful waiting, progressive disease)
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Adenoid Cystic Carcinoma | Adenoid Cystic Carcinoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (5)
- label
- 1
- description
- No evident disease
- label
- 2
- description
- Metastatic Disease; Watchful Waiting: Tumors bearing NOTCH Mutation
- label
- 3
- description
- Metastatic Disease; Watchful Waiting: Tumors bearing Notch Wild Type
- label
- 4
- description
- Progressive Disease: Tumors bearing NOTCH Mutation
- label
- 5
- description
- Progressive Disease: Tumors bearing Notch Wild Type
Primary outcomes (2)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Participant must be a person diagnosed with ACC who is 18 years or older 2. For patients with metastatic disease; watchful waiting or progressive disease, participants must know the results of molecular profiling of their tumor 3. Histologically-confirmed diagnosis of ACC with written proof of disease and molecular profile of tumor provided. This can be a note showing genetic diagnosis from a relevant testing laboratory, physician consult notes, a medical record of diagnosis, or any other single piece of documentation that connects your name/the patient's name with ACC. 4. Able to read, write and understand English, Hebrew, Arabic, or Russian 5. Able to grant informed consent 6. Willing to participate in a 45-to-60-minute telephone interview, including follow up questions (if necessary) Exclusion Criteria: 1\. Inability to meet any of the inclusion criteria
References
Publications (0)
Data not yet available
No reference posted for this study.